Furthermore, FMC-376, a novel dual KRAS G12C (ON) and (OFF) inhibitor, has shown anti-tumor activity in vivo, suggesting the ability to overcome the resistance to KRAS G12C (OFF) inhibitors (17). This evidence concerns the gene KRAS and neoplasm.